Burning Rock Biotech (NASDAQ:BNR) Director Purchases $216,402.40 in Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 24,760 shares of the stock in a transaction on Thursday, June 11th. The shares were acquired at an average cost of $8.74 per share, for a total transaction of $216,402.40. Following the completion of the transaction, the director directly owned 17,697,436 shares in the company, valued at $154,675,590.64. The trade was a 0.14% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The stock was bought at an average price of $9.00 per share, for a total transaction of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $9.25 per share, with a total value of $1,942,500.00.

Burning Rock Biotech Price Performance

Burning Rock Biotech stock opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a twelve month low of $3.23 and a twelve month high of $41.72. The stock has a 50 day moving average of $12.35 and a two-hundred day moving average of $19.96. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $103.31 million, a price-to-earnings ratio of -11.98 and a beta of 1.32.

Burning Rock Biotech (NASDAQ:BNR) last released its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The business had revenue of $15.66 million for the quarter, compared to analyst estimates of $19.21 million.

Institutional Trading of Burning Rock Biotech

A number of institutional investors have recently modified their holdings of BNR. Renaissance Technologies LLC grew its holdings in Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after acquiring an additional 4,290 shares during the period. Marshall Wace LLP acquired a new stake in Burning Rock Biotech in the fourth quarter valued at $220,000. Crcm LP boosted its position in shares of Burning Rock Biotech by 121.8% during the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock worth $9,902,000 after purchasing an additional 269,851 shares in the last quarter. Finally, Prospera Financial Services Inc grew its stake in shares of Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares during the period. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BNR. Wall Street Zen downgraded shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Burning Rock Biotech presently has a consensus rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.